Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
6576140
Reference Type
Journal Article
Title
Pulmonary function and functional capacity cut-off point to establish sarcopenia and dynapenia in patients with COPD
Author(s)
Kamal Mansour, KM; Goulart, C; Soares de Carvalho-Junior, LC; Trimer, R; Borghi-Silva, A; Goncalves da Silva, AL; ,
Year
2019
Is Peer Reviewed?
Yes
Journal
Jornal Brasileiro de Pneumologia
ISSN:
1806-3713
Publisher
SOC BRASILEIRA PNEUMOLOGIA TISIOLOGIA
Location
BRASILIA DF
Volume
45
Issue
6
Page Numbers
7
Language
English
PMID
31644702
DOI
10.1590/1806-3713/e20180252
Web of Science Id
WOS:000505050800011
URL
http://
://WOS:000505050800011
Exit
Abstract
Objective: To establish a cut-off point for clinical and functional variables to determinate sarcopenia and dynapenia in COPD patients, and to analyze the impact of skeletal muscle dysfunction (SMD) on these variables. Methods: Cross-sectional study, screened COPD patients for sarcopenia or dynapenia through low muscle mass and hand grip strength (HGS). Clinical variables: pulmonary function, respiratory muscle strength and functional capacity (FC). The precision of the variables in determining points of predictive cut-off for sarcopenia or dynapenia were performed using the Receiver Operating Characteristic curve and two-way analysis of variance. Results: 20 COPD patients stratified for sarcopenia (n = 11) and dynapenia (n = 07). Sarcopenia group presented lower lean mass and lower maximal inspiratory pressure (MIP), decreased HGS, reduced FC (p<0.050). Dynapenia group presented reduced MIP, lower HGS and walked a shorter distance at Incremental shuttle walk test (ISWT) (p<0.050). We found cut-off points of forced expiratory volume in one second (FEV1), MIP and maximal expiratory pressure (MEP) and ISWT. It is possible to identify sarcopenia or dynapenia in these patients. We found the coexistence of the conditions (SMD effect) in COPD - reduction in the distance in the ISWT (p = 0.002) and %ISWT (p = 0.017). Conclusion: In moderate to very severe COPD patients the sarcopenia could be predicted by FEV1 (%predicted) < 52, MIP < 73 cmH(2)O, MEP < 126 cmH2O and distance traveled of < 295 m in ISWT. Whereas dynapenia could be predicted by FEV1 < 40%, MIP < 71 cmH2O, MEP < 110 cmH2O and distance of < 230 m traveled in ISWT.
Keywords
Sarcopenia; Chronic obstructive pulmonary disease; Musculoskeletal; muscle dysfunction; reference values; epidemiology; frailty; severity; mobility; overlap; Respiratory System
Tags
IRIS
•
Inorganic Mercury Salts (2)
Mercuric Sulfide
Litsearch 2019-2020
WoS
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity